×
About 27,831 results

ALLMedicine™ Glucagon Center

Research & Reviews  13,415 results

Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin...
https://doi.org/10.1080/1061186X.2021.1894434
Journal of Drug Targeting; Poudwal S, Misra A et. al.

Feb 23rd, 2021 - A growing demand for insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RA) is observed, considering the progressive nature of diabetes and the potential therapeutic role of peptides in its treatment. However, the chronic parenteral admi...

Glucagon blockade restores functional β-cell mass in type 1 diabetic mice and enhances ...
https://doi.org/10.1073/pnas.2022142118
Proceedings of the National Academy of Sciences of the Un... Wang MY, Dean ED et. al.

Feb 23rd, 2021 - We evaluated the potential for a monoclonal antibody antagonist of the glucagon receptor (Ab-4) to maintain glucose homeostasis in type 1 diabetic rodents. We noted durable and sustained improvements in glycemia which persist long after treatment ...

Reducing alcohol and/or cocaine-induced reward and toxicity via an epidermal stem cell-...
https://doi.org/10.1038/s41380-021-01043-y 10.1001/jamapsychiatry.2015.0584 10.1016/S0006-3223(97)00426-5 10.4172/2155-6105.1000281 10.1111/j.1471-4159.1991.tb08205.x 10.1046/j.1360-0443.2002.00158.x 10.1111/j.1476-5381.1993.tb13569.x 10.1300/J069v16n03_08 10.1152/physrev.00034.2006 10.1016/S0306-4522(03)00383-X 10.1523/JNEUROSCI.17-02-00851.1997 10.1016/j.physbeh.2019.112771 10.1016/j.celrep.2015.06.062 10.1038/npp.2015.362 10.1371/journal.pone.0077284 10.1016/j.psyneuen.2012.11.009 10.1111/adb.12583 10.1016/j.neuropharm.2018.01.013 10.1016/j.physbeh.2019.03.026 10.1016/j.pharmthera.2014.11.011 10.1073/pnas.0507332102 10.1038/sj.npp.1301666 10.4155/fmc.11.181 10.1155/2011/601047 10.1016/j.stem.2017.06.016 10.1038/s41551-018-0293-z 10.1016/0091-3057(95)00098-H 10.1016/j.legalmed.2012.04.008 10.1124/jpet.102.041350 10.1002/syn.10226 10.1074/jbc.M115.671743 10.1126/scitranslmed.3009540 10.1016/j.psyneuen.2019.02.006 10.1385/JMN:18:1-2:07 10.1517/14740338.7.5.571 10.1523/JNEUROSCI.4520-07.2008 10.1007/s00213-018-5024-3 10.1016/0305-4179(94)90017-5 10.1038/nature24487 10.1210/en.2009-0915 10.1523/JNEUROSCI.3464-14.2015 10.1016/j.jchemneu.2008.07.009 10.1038/nn.4540 10.1111/jnc.14008
Molecular Psychiatry; Kong Q, Li Y et. al.

Feb 23rd, 2021 - Alcohol use disorder (AUD) is one of the foremost public health problems. Alcohol is also frequently co-abused with cocaine. There is a huge unmet need for the treatment of AUD and/or cocaine co-abuse. We recently demonstrated that skin grafts gen...

The results are in: Cardiovascular benefits of glucagon-like peptide-1 receptor agonist...
https://doi.org/10.1177/2047487320918722
European Journal of Preventive Cardiology; Chan JSK

Feb 21st, 2021 - The results are in: Cardiovascular benefits of glucagon-like peptide-1 receptor agonists - a trial sequential analysis.|2021|Chan JSK,|

see more →

Guidelines  15 results

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Repor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971782
Diabetes Care; Buse JB, Wexler DJ et. al.

Dec 20th, 2019 - The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycemia, based on important research findings from large cardiovascular outcomes trials...

FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes
https://www.novonordisk-us.com/media/news-releases.html?122973

Sep 19th, 2019 - Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide) tablets 7 mg or 14 mg for adults with type 2 diabetes that along with diet and exercise may improve blood sugar (glucose).1 Rybelsus...

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30311-0/fulltext
The Lancet Diabetes & Endocrinology; Lingvay,I.,et al

Sep 16th, 2019 - Existing guidelines for management of type 2 diabetes recommend a patient-centred approach to guide the choice of pharmacological agents. Although glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter-2 (SGLT2) inhibit...

Xeris Pharmaceuticals Receives U.S. Fda Approval For Gvoke™ (Glucagon), The First Ready-to-use Stable Liquid Glucagon For Severe Hypoglycemia
https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris-pharmaceuticals-receives-us-fda-approval-gvoketm-glucagon

Sep 9th, 2019 - Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announced today that it has received reg...

Should Adults With Prediabetes Be Prescribed Metformin To Prevent Diabetes Mellitus? Yes: High-Quality Evidence Supports Metformin Use in Persons at High Risk
https://www.aafp.org/afp/2019/0801/p134.html
American Family Physician; Moin,T.

Aug 1st, 2019 - A surge in the prevalence of prediabetes1 highlights the importance of improving prediabetes awareness and engaging in strategies to lower the risk of type 2 diabetes mellitus. Based on evidence from randomized controlled trials and observational ...

see more →

Drugs  91 results see all →

Clinicaltrials.gov  13,831 results

Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin...
https://doi.org/10.1080/1061186X.2021.1894434
Journal of Drug Targeting; Poudwal S, Misra A et. al.

Feb 23rd, 2021 - A growing demand for insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RA) is observed, considering the progressive nature of diabetes and the potential therapeutic role of peptides in its treatment. However, the chronic parenteral admi...

Glucagon blockade restores functional β-cell mass in type 1 diabetic mice and enhances ...
https://doi.org/10.1073/pnas.2022142118
Proceedings of the National Academy of Sciences of the Un... Wang MY, Dean ED et. al.

Feb 23rd, 2021 - We evaluated the potential for a monoclonal antibody antagonist of the glucagon receptor (Ab-4) to maintain glucose homeostasis in type 1 diabetic rodents. We noted durable and sustained improvements in glycemia which persist long after treatment ...

Reducing alcohol and/or cocaine-induced reward and toxicity via an epidermal stem cell-...
https://doi.org/10.1038/s41380-021-01043-y 10.1001/jamapsychiatry.2015.0584 10.1016/S0006-3223(97)00426-5 10.4172/2155-6105.1000281 10.1111/j.1471-4159.1991.tb08205.x 10.1046/j.1360-0443.2002.00158.x 10.1111/j.1476-5381.1993.tb13569.x 10.1300/J069v16n03_08 10.1152/physrev.00034.2006 10.1016/S0306-4522(03)00383-X 10.1523/JNEUROSCI.17-02-00851.1997 10.1016/j.physbeh.2019.112771 10.1016/j.celrep.2015.06.062 10.1038/npp.2015.362 10.1371/journal.pone.0077284 10.1016/j.psyneuen.2012.11.009 10.1111/adb.12583 10.1016/j.neuropharm.2018.01.013 10.1016/j.physbeh.2019.03.026 10.1016/j.pharmthera.2014.11.011 10.1073/pnas.0507332102 10.1038/sj.npp.1301666 10.4155/fmc.11.181 10.1155/2011/601047 10.1016/j.stem.2017.06.016 10.1038/s41551-018-0293-z 10.1016/0091-3057(95)00098-H 10.1016/j.legalmed.2012.04.008 10.1124/jpet.102.041350 10.1002/syn.10226 10.1074/jbc.M115.671743 10.1126/scitranslmed.3009540 10.1016/j.psyneuen.2019.02.006 10.1385/JMN:18:1-2:07 10.1517/14740338.7.5.571 10.1523/JNEUROSCI.4520-07.2008 10.1007/s00213-018-5024-3 10.1016/0305-4179(94)90017-5 10.1038/nature24487 10.1210/en.2009-0915 10.1523/JNEUROSCI.3464-14.2015 10.1016/j.jchemneu.2008.07.009 10.1038/nn.4540 10.1111/jnc.14008
Molecular Psychiatry; Kong Q, Li Y et. al.

Feb 23rd, 2021 - Alcohol use disorder (AUD) is one of the foremost public health problems. Alcohol is also frequently co-abused with cocaine. There is a huge unmet need for the treatment of AUD and/or cocaine co-abuse. We recently demonstrated that skin grafts gen...

More Published Data on 'Game-Changer' Drug for Obesity
https://www.medscape.com/viewarticle/946392

Feb 23rd, 2021 - Results showing once-weekly subcutaneous semaglutide, as an adjunct to intensive behavioral therapy and an initial low calorie diet, induced weight loss that was 10.3% greater compared with placebo over 68 weeks in people with obesity or overweigh...

see more →

News  477 results

More Published Data on 'Game-Changer' Drug for Obesity
https://www.medscape.com/viewarticle/946392

Feb 23rd, 2021 - Results showing once-weekly subcutaneous semaglutide, as an adjunct to intensive behavioral therapy and an initial low calorie diet, induced weight loss that was 10.3% greater compared with placebo over 68 weeks in people with obesity or overweigh...

Semaglutide for Weight Loss? A Good First STEP, With Caveats
https://www.medscape.com/viewarticle/945630

Feb 9th, 2021 - The phase 3a STEP 1 trial that investigated the use of semaglutide (Novo Nordisk), a glucagon-like peptide-1 (GLP-1) agonist, for weight loss is aptly named, some say. "In sum, we have a long way to go to control the obesity epidemic. "Pressing Ne...

What's the Best Second-Line Drug Class for Type 2 Diabetes?
https://www.medscape.com/viewarticle/945430

Feb 7th, 2021 - Sodium-glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes appear to confer greater cardiovascular benefit than glucagon-like peptide-1 (GLP-1) receptor agonists among older adults with a history of cardiovascular disease (CVD), ac...

Meta-analysis Shows Efficacy of GLP-1 Agonists in Children with T2DM, Obesity
https://www.medscape.com/viewarticle/943944

Jan 12th, 2021 - Takeaway Glucagon-like peptide-1 (GLP-1) agonists are efficacious in treating children with obesity and type 2 diabetes mellitus (T2DM).

FDA OKs First Generic Injected Glucagon for Hypoglycemia
https://www.medscape.com/viewarticle/943385

Dec 29th, 2020 - The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid. The FDA determined that Amphastar Pharmaceuticals' Glucagon ...

see more →

Patient Education  2 results see all →